However, clinical trials with Pegkantratinib (CT327, SNA-120)—antagonist of other neutrophin receptors—TrkA in patients with pruritic skin disorders such as AD or psoriasis are ongoing or have already been completed [56,57]. Here, NTRK1 is linked to skin disorder.